Terlipressin

Objective To evaluate the clinical efficacy of Terlipressin for treatment of intractable septic shock .

目的旨在探讨特利加压素（Terlipressin）对脓毒血症难治性休克的临床应用价值。

Protective strategy of Terlipressin on the remnant livers after major hepatectomy in rats residual expansion of tank volume

特利加压素对肝大部切除术后大鼠小体积残肝的保护性治疗罐体容积残余变形值

Conclusion Terlipressin have clinical therapeutic effects for intractable septic shock .

结论对严重脓毒血症难治性休克，特利加压素具有一定的临床应用价值。

Terlipressin ameliorates portal hyperperfusion injury by effectively reducing portal pressure and portal blood flow .

Terlipressin能有效缓解门脉高灌注状态，达到降低门脉压力及血流量的治疗效果，进而减轻门脉高灌注损伤。

Effect observe of terlipressin on hepatorenal syndrome

特利加压素治疗肝肾综合征的疗效观察

No significant difference between endoscopic ligation group and terlipressin group in hemostatic efficacy ( P > 0 . 05 ) .

特利加压素组和内镜套扎组的72小时止血率则没有差别（P＞0.05）。

Effects of terlipressin and pituitrin on portal hemodynamics in rabbits with prehepatic portal hypertension

特利加压素、垂体后叶素对正常及门脉高压兔门脉血流动力学影响的研究

Results Success of therapy in terlipressin group ( 80.5 % ) was similar to that in stilamin group ( 83.7 % ) .

结果特利加压素组治疗有效率（805%）类似于施他宁组（837%）；

However , 60 minutes after injection , the roles of pituitrin vanished but terlipressin still had significant effects ( P 0.05 ) .

但注射药物后60min，垂体后叶素的作用基本消失，而特利加压素仍有明显的降压作用（P0.05）。

Results 6h after the administer of Terlipressin , patients ' MAP rose and shock index number reduced dramatically , 12h after treatment by Terlipressin , patients ' HR improved significantly ( P0.01 ) .

结果特利加压素使用6h后平均动脉压明显上升、休克指数明显下降，使用12h后心率、尿量明显改善。

Conclusion : Terlipressin improved the clinical syndromes and prognosis of patients with hepatorenal syndrome ( HRS ), reduced the level of blood creatinine , increased the urine volume . Terlipressin will provid us a new way to treat patients with hepatorenal syndrome ( HRS ) .

结论：特利加压素治疗肝肾综合征可改善患者临床症状及预后，降低血肌酐水平，增加尿量，为治疗该病提供新的措施。